Circius Pharma AB – Trademark Portfolio

Entity Type: 16

Circius Pharma AB holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include OTINOVA, OTOVENT, TINEARITY, and E DUEARITY.

Södra Långebergsgatan 34-36

SE-436 32 ASKIM

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

TINEARITY
TINEARITY
Registered 2023
OTINOVA
OTINOVA
Registered 2022
OTOVENT
OTOVENT
Registered 2006

Trademark Classifications

Circius Pharma AB's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (4 filings)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Circius Pharma AB have?

Circius Pharma AB has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 abandoned.

What trademark classes does Circius Pharma AB file in?

Circius Pharma AB files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Circius Pharma AB's most well-known trademarks?

Circius Pharma AB's registered trademark portfolio includes well-known marks such as OTINOVA, OTOVENT, TINEARITY, and E DUEARITY. These are among 4 currently registered trademarks in the portfolio.

What is Circius Pharma AB's trademark registration success rate?

Circius Pharma AB has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.